1. P551: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE IN PREVIOUSLY UNTREATED PATIENTS WITH TP53-MUTANT ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Daver, N. G.; Vyas, P.; Chao, M. P.; Xing, G.; Renard, C.; Ramsingh, G.; Sallman, D. A.; Wei, A. H. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA. (23rd June 2022) Authors: Vyas, P.; Daver, N. G.; Chao, M. P.; Xing, G.; Renard, C.; Ramsingh, G.; Wei, A. H.; Sallman, D. A. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P740: IMPACT OF MAGROLIMAB IN COMBINATION WITH AZACITIDINE ON RED BLOOD CELLS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR MDS). (23rd June 2022) Authors: Chen, J. Y.; Johnson, L.; McKenna, K. M.; Choi, T. S.; Duan, J.; Feng, D.; Tsai, J. M.; Garcia-Martin, N.; Sompalli, K.; Maute, R.; Vyas, P.; Majeti, R.; Takimoto, C. H. M.; Liu, J.; Ramsingh, G.; Chao, M. P.; Volkmer, J.-P.; Weissman, I. L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 635 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗